Scarica l'app Stockscreener
45.19
0.87%
0.39
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Storia dei dividendi
Precedente Chiudi:
$44.80
Aprire:
$44.8
Volume 24 ore:
5.40M
Relative Volume:
1.38
Capitalizzazione di mercato:
$19.36B
Reddito:
$2.35B
Utile/perdita netta:
$1.30B
Rapporto P/E:
25.84
EPS:
1.7487
Flusso di cassa netto:
$1.05B
1 W Prestazione:
+1.21%
1M Prestazione:
+11.97%
6M Prestazione:
+23.94%
1 anno Prestazione:
+39.22%
Intervallo 1D:
$44.71
$45.91
Intervallo di 1 settimana:
$42.50
$45.91
Portata 52W:
$29.66
$45.91
Royalty Pharma Plc Stock (RPRX) Company Profile
Nome
Royalty Pharma Plc
Settore
Industria
Telefono
(212) 883-0200
Indirizzo
110 EAST 59TH STREET, NEW YORK, NY
Compare RPRX vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RPRX
Royalty Pharma Plc
|
45.19 | 19.19B | 2.35B | 1.30B | 1.05B | 1.7487 |
|
VRTX
Vertex Pharmaceuticals Inc
|
491.47 | 117.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
803.17 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
821.96 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.40 | 40.75B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.07 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
Royalty Pharma Plc Stock (RPRX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-30 | Aggiornamento | UBS | Neutral → Buy |
| 2025-09-30 | Iniziato | Goldman | Buy |
| 2025-05-16 | Iniziato | Morgan Stanley | Overweight |
| 2024-06-03 | Downgrade | UBS | Buy → Neutral |
| 2022-06-14 | Ripresa | UBS | Buy |
| 2022-05-13 | Iniziato | Scotiabank | Sector Outperform |
| 2022-04-27 | Iniziato | Goldman | Buy |
| 2022-04-14 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2022-04-06 | Ripresa | Morgan Stanley | Overweight |
| 2021-10-29 | Aggiornamento | Citigroup | Neutral → Buy |
| 2021-07-30 | Iniziato | Tigress Financial | Buy |
| 2020-11-09 | Aggiornamento | UBS | Neutral → Buy |
| 2020-07-14 | Iniziato | Evercore ISI | In-line |
| 2020-07-13 | Iniziato | BofA Securities | Buy |
| 2020-07-13 | Iniziato | Citigroup | Neutral |
| 2020-07-13 | Iniziato | Cowen | Outperform |
| 2020-07-13 | Iniziato | Goldman | Neutral |
| 2020-07-13 | Iniziato | JP Morgan | Neutral |
| 2020-07-13 | Iniziato | Morgan Stanley | Equal-Weight |
| 2020-07-13 | Iniziato | SunTrust | Buy |
| 2020-07-13 | Iniziato | UBS | Neutral |
Mostra tutto
Royalty Pharma Plc Borsa (RPRX) Ultime notizie
Wall Street Zen Downgrades Royalty Pharma (NASDAQ:RPRX) to Buy - MarketBeat
Royalty Pharma targets 3%–8% royalty receipts growth in 2026 while advancing $4.7B in transactions - MSN
Royalty Pharma Earnings Call Balances Strength And Risk - TipRanks
New South Capital Management Inc. Purchases 31,694 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Cookson Peirce & Co. Inc. Buys 338,623 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Will Royalty Pharma plc stock see insider buyingMarket Weekly Review & Growth Focused Stock Reports - mfd.ru
Risks Report: Is Royalty Pharma plc likely to announce a buybackWeekly Stock Recap & Intraday High Probability Setup Alerts - baoquankhu1.vn
Arrowhead Stock Has Skyrocketed 290% in One Year, and One Fund Trimmed Its Holdings by $4 Million - AOL.com
Royalty Pharma: Strong Execution And Visible Pipeline Support Our Buy View (NASDAQ:RPRX) - Seeking Alpha
S P Trends: Is Royalty Pharma plc likely to announce a buybackWeekly Stock Recap & Free Risk Controlled Daily Trade Plans - baoquankhu1.vn
Royalty Pharma price target raised to $51 from $45 at Goldman Sachs - TipRanks
Royalty Pharma plc (NASDAQ:RPRX) Q4 2025 Earnings Call Transcript - Insider Monkey
BofA Securities reiterates Buy rating on Royalty Pharma stock with $54 target - Investing.com Nigeria
BofA Securities Reiterates Buy Rating on Royalty Pharma (RPRX) - StreetInsider
Royalty Pharma's Disciplined Capital Allocation Approach and Appealing Market Growth Bolster Outlook - Morningstar
Royalty Pharma PLC (RPRX): A Strategic SWOT Insight - GuruFocus
Royalty Pharma Q4 2025 slides: double-digit growth amid synthetic royalty expansion - Investing.com Nigeria
Royalty Pharma stock hits 52-week high at 44.94 USD By Investing.com - Investing.com Nigeria
UBS and Citi are bullish on Royalty Pharma plc (RPRX) – here’s why - MSN
Royalty Pharma earnings beat by $0.22, revenue fell short of estimates - Investing.com UK
Royalty Pharma plc (RPRX) Reports Q4 results - StreetInsider
Royalty Pharma earnings beat by $0.22, revenue topped estimates - Investing.com Nigeria
Royalty Pharma (NASDAQ:RPRX) Sets New 1-Year HighHere's What Happened - MarketBeat
Royalty Pharma (NASDAQ:RPRX) Will Pay A Larger Dividend Than Last Year At $0.235 - simplywall.st
Royalty Pharma stock hits 52-week high at 44.94 USD - Investing.com
Royalty Pharma (NASDAQ:RPRX) Announces Quarterly Earnings Results, Beats Estimates By $0.13 EPS - MarketBeat
RPRX: Double-digit growth, early capital deployment, and rising synthetic royalties drive strong outlook - TradingView
Earnings call transcript: Royalty Pharma beats Q4 2025 forecasts with strong EPS - Investing.com India
RPRX: Double-digit growth, early capital deployment, and strong 2026 outlook with cost savings - TradingView
Royalty Pharma Q4 Earnings Call Highlights - Yahoo Finance
Here's What Key Metrics Tell Us About Royalty Pharma (RPRX) Q4 Earnings - Yahoo Finance
Royalty Pharma plc Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
Royalty Pharma plc Provides Earnings Guidance for the Full Year 2026 - marketscreener.com
Royalty Pharma plc SEC 10-K Report - TradingView
Royalty Pharma (NASDAQ:RPRX) Reports Sales Below Analyst Estimates In Q4 CY2025 Earnings - Finviz
Royalty Pharma PLC-CL A (NASDAQ:RPRX) Shares Dip Despite Strong Portfolio Growth and 2026 Guidance Beat - ChartMill
Royalty Pharma Reports Q4 and Full Year 2025 Results - TradingView
Royalty Pharma's Q4 Net Income, Revenue Rise - marketscreener.com
Royalty Pharma reports Q4 portfolio receipts of $874M - TipRanks
Royalty Pharma Plc Bottom Line Advances In Q4 - Nasdaq
Royalty Pharma Q4 Earnings Report: What Investors Need to Know - Benzinga
Royalty Pharma earnings in focus after $4.7B deal spree By Investing.com - Investing.com South Africa
Royalty Pharma earnings in focus after $4.7B deal spree - Investing.com
Royalty Pharma's Earnings: A Preview - Benzinga
Exploring Analyst Estimates for Royalty Pharma (RPRX) Q4 Earnings, Beyond Revenue and EPS - Yahoo Finance Australia
UBS and Citi Are Bullish on Royalty Pharma Plc (RPRX) – Here’s Why - Insider Monkey
Allianz Asset Management GmbH Sells 127,319 Shares of Royalty Pharma PLC $RPRX - MarketBeat
What To Expect From Royalty Pharma's (RPRX) Q4 Earnings - Finviz
What To Expect From Royalty Pharma’s (RPRX) Q4 Earnings - Yahoo Finance UK
Alps Advisors Inc. Acquires New Shares in Royalty Pharma PLC $RPRX - MarketBeat
Shorts Report: Will Royalty Pharma plc benefit from rate cutsJuly 2025 Outlook & Stock Timing and Entry Methods - baoquankhu1.vn
Royalty Pharma Plc Azioni (RPRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.12%
0.35%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):